The Effect of Conventional Immunosuppressive Therapy on Cytokine Serum Levels in Pemphigus Vulgaris Patients
-
Hossein Mortazavi
,
Nafiseh Esmaili
,
Somayeh Khezri
,
Ali Khamesipour
,
Iman Vasheghani Farahani
,
Maryam Daneshpazhooh
,
Nima Rezaei
Abstract
Pemphigus vulgaris is an autoimmune disease, in which the role of Th17 cytokines needs to be further explored. This study was performed to assess serum levels of three interleukins (IL) required for Th17 differentiation (IL-1β, IL-6 and IL-23) and two specific Th17 cytokines (IL-17 and IL-22) in a group of patients with pemphigus vulgaris, at baseline, 3 weeks and 6 months after of treatment. Correlations between anti-desmogleins and cytokines with disease severity as well as the influence of therapy on the above factors were assessed.
Forty-three first-admitted pemphigus vulgaris patients with the active disease entered the study, but only 31 completed the study. Forty-five healthy volunteers were recruited as a control group. The patients were treated with conventional immunosuppressive therapy (oral prednisolone and azathioprine). Cytokines and anti-desmogleins were measured, using enzyme- linked immunosorbent assay. General linear model was used to evaluate the changes over time.
In patients at baseline, mean serum level of IL-6 was higher, while mean levels of IL-1β and IL-22 were lower than the controls. After 3 weeks of therapy, IL-1β and IL-6 levels showed a decreasing trend, whereas IL-22 showed an increasing trend. Mean anti-desmogleins 1 and 3 values decreased significantly during the time. Anti-desmoglein values were significantly correlated with disease severity.
In conclusion, IL-1β and IL-6 could be involved in the pathogenesis of pemphigus vulgaris.
The positive trend of IL-22 is a new finding and should be confirmed by further studies.
1. Hertl M, Veldman C. T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev 2003; 2(5):278-83.
2. Hertl M, Eming R. Autoimmune bullous skin disorders. In: Hertl M, editor. Autoimmune diseases of the skin (pathogenesis, diagnosis, management). Wien: Springer 2011:34-48.
3. Satyam A, Khandpur S, Sharma VK, Sharma A.Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease- Pemphigus vulgaris. Immunol Invest 2009; 38(6):498-509.
4. Mortazavi H, Amirzargar AA, Valikhani M, Hallaji Z, Daneshpazhouh M, Nazemi Tabrizi MJ, et al. The Influence of Treatment of Pemphigus Vulgaris on the Serum Level of Cytokines. Iranian Journal of Dermatology 2008; 11(1):11-6.
5. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148(1):32-46.
6. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128(5):1064-7.
7. Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci 2009;53(3):228-31.
8. Sinha AA. Constructing immunoprofiles to deconstruct disease complexity in pemphigus. Autoimmunity 2012; 45(1):36-43.
9. Giordano CN, Sinha AA. Cytokine networks in Pemphigus vulgaris: An integrated viewpoint. Autoimmunity 2012; 45(6):427-39.
10. Eagar TN, Miller SD. Helper T-cell subsets and control of the inflammatory response. In: Rich RR, Fleisher TA, Shearer WT, Schroeder Jr. HW, Frew AJ, Weyand CM, editors. Clinical Immunology: Principles and Practice. China: Elsevier Saunders,2013: 203-14.
11. Abbas A, Lichtman A, Pillai S. Cellular and molecular immunology. 7 ed. Philadelphia: Elsevier Saunders; 2012.
12. Ludwig RJ, Schmidt E. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis? G Ital Dermatol Venereol 2009; 144(4):339-49.
13. Chams-Davatchi C. Prevalence and treatment of pemphigus in Iran. Dermatol Clin 2011 ; 29(4):681-3.
14. Sharma VK, Prasad HR, Khandpur S, Kumar A.Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris. Int J Dermatol 2006; 45(5):518-22.
15. Mortazavi H, Kiavash K, Esmaili N, Chams- Davatchi C. Correlation of pemphigus vulgaris antibody titers by indirect immunofluorescence with activity of disease based on pemphigus area and activity score (PAAS). Acta Medica Iranica 2008; 46(3):239-44.
16. Narbutt J, Lukamowicz J, Bogaczewicz J, Sysa- Jedrzejowska A, Torzecka JD, Lesiak A. Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediators Inflamm 2008; 2008:875394.
17. Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immunol 2001; 100(2):172-80.
18. Mortazavi H, Babaeijandaghi F, Akbarzadeh M, Rezaei N, Amirzargar AA, Daneshpazhooh M, et al. The influence of systemic therapy on the serum levels of IL-6 and IL-8 in pemphigus vulgaris. J Eur Acad Dermatol Venereol 2011; 27(3):387-90.
19. Paul WE. Fundamental Immunology. 7 ed.Philadelphia: Lippincott williams & wilkins, 2013.
20. Cho KA, Suh JW, Lee KH, Kang JL, Woo SY. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1beta by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol 2012; 24(3):147-58.
21. Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37(1):81-5.
22. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009; 68(4):604-6.
23. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA.Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009;9(4):447-53.
24. Quesniaux V, Ryffel B, Padova FD. Th17 cells: Role in inflammation and autoimmune diseases. 1 ed. Parnham MJ, editor. Berlin: birkhäuser verlag AG; 2009.
25. Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C.IL-17 and IL-22: siblings, not twins. Trends Immunol 2010; 31(9):354-61.
26. Scerri L. Azathioprine in dermatological practice.An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999; 455:343-8.
27. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55(3):369-89.
28. Tanikawa A, Amagai M. Pemphigus treatment in Japan. Dermatol Clin 2011; 29(4):685-6.
29. D'Auria L, Bonifati C, Mussi A, D'Agosto G, De Simone C, Giacalone B, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997; 8(4):383-7.
30. Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine 2008; 41(3):315-21.
31. Stern JN, Keskin DB, Barteneva N, Zuniga J, Yunis EJ, Ahmed AR. Possible role of natural killer cells in pemphigus vulgaris - preliminary observations. Clin Exp Immunol 2008; 152(3):472-81.
32. Chriguer RS, Roselino AM, de Castro M.Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus. J Clin Immunol 2012; 32(4):786-93.
33. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153(1):222-3.
34. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153(2):448-9.
| Files | ||
| Issue | Vol 13, No 3 (2014) | |
| Section | Articles | |
| Keywords | ||
| Desmogleins Interleukin-1beta Interleukin-6 Interleukin-17 Interleukin-22 Interleukin-23 Pemphigus vulgaris | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
